Moderna Future Growth
Future criteria checks 5/6
Moderna is forecast to grow earnings and revenue by 68.8% and 20.8% per annum respectively. EPS is expected to grow by 67.8% per annum. Return on equity is forecast to be -5.5% in 3 years.
Key information
68.8%
Earnings growth rate
67.8%
EPS growth rate
| Biotechs earnings growth | 24.7% |
| Revenue growth rate | 20.8% |
| Future return on equity | -5.5% |
| Analyst coverage | Good |
| Last updated | 31 May 2024 |
Recent future growth updates
Recent updates
Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor
May 23Moderna Q1: A Promising Pipeline Is Undervalued
May 15We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed
Apr 30
Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares
Apr 22Moderna: Considering The Cancer Vaccine Angle
Apr 11Moderna Continues To Build A Pipeline
Apr 03Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play
Mar 27Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Feb 27Moderna: Counting On Pipeline Too Much
Feb 23Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World
Feb 16Moderna: Fade 2025 Outlook
Jan 15Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%
Dec 29Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024
Nov 03Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value Estimate
Oct 18Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6,630 | -341 | -837 | -231 | 18 |
| 12/31/2025 | 4,836 | -1,964 | -1,879 | -1,359 | 24 |
| 12/31/2024 | 4,175 | -2,688 | -2,530 | -1,423 | 24 |
| 3/31/2024 | 5,153 | -5,968 | -3,672 | -2,882 | N/A |
| 12/31/2023 | 6,848 | -4,714 | -3,825 | -3,118 | N/A |
| 9/30/2023 | 9,121 | -3,466 | -2,657 | -2,078 | N/A |
| 6/30/2023 | 10,654 | 1,207 | -754 | -226 | N/A |
| 3/31/2023 | 15,059 | 4,784 | 612 | 993 | N/A |
| 12/31/2022 | 19,263 | 8,362 | 4,581 | 4,981 | N/A |
| 9/30/2022 | 21,390 | 11,765 | 6,201 | 6,629 | N/A |
| 6/30/2022 | 22,995 | 14,055 | 9,215 | 9,653 | N/A |
| 3/31/2022 | 22,600 | 14,638 | 13,031 | 13,412 | N/A |
| 12/31/2021 | 18,471 | 12,202 | 13,336 | 13,620 | N/A |
| 9/30/2021 | 11,831 | 7,061 | 11,386 | 11,574 | N/A |
| 6/30/2021 | 7,019 | 3,495 | 9,083 | 9,191 | N/A |
| 3/31/2021 | 2,732 | 598 | 5,007 | 5,104 | N/A |
| 12/31/2020 | 803 | -747 | 1,959 | 2,027 | N/A |
| 9/30/2020 | 246 | -597 | 613 | 664 | N/A |
| 6/30/2020 | 106 | -488 | -374 | -336 | N/A |
| 3/31/2020 | 52 | -505 | -451 | -421 | N/A |
| 12/31/2019 | 60 | -514 | -491 | -459 | N/A |
| 9/30/2019 | 82 | -535 | -489 | -451 | N/A |
| 6/30/2019 | 106 | -499 | -482 | -424 | N/A |
| 3/31/2019 | 122 | -459 | -445 | -364 | N/A |
| 12/31/2018 | 135 | -402 | -437 | -331 | N/A |
| 9/30/2018 | 192 | -299 | -447 | -343 | N/A |
| 6/30/2018 | 192 | -280 | -412 | -305 | N/A |
| 3/31/2018 | 199 | -266 | -432 | -350 | N/A |
| 12/31/2017 | 206 | -270 | N/A | -331 | N/A |
| 12/31/2016 | 108 | -230 | N/A | 67 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MRNA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: MRNA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MRNA is expected to become profitable in the next 3 years.
Revenue vs Market: MRNA's revenue (20.8% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: MRNA's revenue (20.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MRNA is forecast to be unprofitable in 3 years.